A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the safety and efficacy of a combined therapy regimen of RX-0201 plus Gemcitabine, in subjects with metastatic pancreatic cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT02289898

Pancreatic Cancer

COMPLETED PHASE2

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

NCT01298011

Resectable Pancreatic Cancer

COMPLETED PHASE2

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

NCT01461915

Metastatic Pancreatic Cancer

TERMINATED PHASE2

Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer

NCT01231581

Cancer

COMPLETED PHASE2

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

NCT01456585

Adenocarcinoma Pancreas

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects enrolled to assess safety will receive a combination of Gemcitabine plus RX-0201. Gemcitabine will be administered prior to RX-0201 intravenously in a 30-min iv infusion dose at 1000 mg/m2 once weekly for up to 2 cycles; each 4-week cycle consist of 3-week treatment phase followed by 1 week resting phase. RX-0201 will be administered at 250 mg/m2/day in a 24-hour continuous intravenous infusion for up to 2 cycles; each 3-week cycle consists of 2-week treatment phase followed by a 1 week resting phase. (See schedule of assessments)Subjects enrolled to evaluate efficacy will receive a combination of Gemcitabine and RX-0201 as outline above for up to 4 cycles.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

gemcitabine and RX-0201

Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.

RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off.

Group Type EXPERIMENTAL

RX-0201 plus Gemcitabine

Intervention Type DRUG

RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RX-0201 plus Gemcitabine

RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide written informed consent prior to the initiation of study procedures.
* Are \> 18 years of age
* Have metastatic pancreatic cancer.
* Have at least 1 measurable lesion by RECIST criteria.
* Have a Karnofsky Performance Status of \> 70.
* Have at least a 6-month life expectancy as assessed by the investigator.
* Pre-menopausal women must be surgically sterile or agree to use an accepted method of birth control while participating in the study and for 30 days following the last exposure of study drug. Acceptable forms of birth control are: hormonal contraceptives (oral, injectable, transdermal or implant), double-barrier contraceptives (condom or diaphragm with spermicide), and intrauterine device (IUD).
* Male subjects need to either be surgically sterile or agree to use a barrier method of birth control described above during the study and for 30 days following the last exposure to study drug. The subject's agreed upon method of birth control will be discussed and documented in the subjects source document during the screening phase of the study.

Exclusion Criteria

* Are unwilling or unable to provide informed consent.
* Are unwilling or unable to comply with the requirements of the protocol.
* Have been treated with another investigational agent for pancreatic cancer.
* Have any of the following screening laboratory values:

* Hemoglobin \< 8.0 grams/deciliter (g/dL)
* Absolute neutrophil count (ANC) \< 1500/microliter (μL)
* Platelet count \< 100,000/μL
* Serum creatinine \> 1.5 x the institutional upper limit of normal (IULN) creatinine.
* Serum bilirubin \> 1.5 X IULN
* Aspartate transaminase (AST) (serum glutamic oxaloacetic transaminase, SGOT) \> 2 x IULN (\> 5 x IULN in presence of known liver metastasis)
* Alanine transaminase (ALT) (serum glutamate pyruvate transaminase, SGPT) \> 2 x IULN (\> 5 x IULN in presence of known liver metastasis)
* Have a prothrombin time \>1.25 x IULN on screening laboratory assessments.
* HCV or HBsAg positive subjects
* Have received therapeutic dose of either warfarin or heparin within 21 days before Day 1 (the first day of dosing; prophylactic use of warfarin or heparin) to maintain patency of indwelling IV catheters/lines is allowed
* Have a history of brain cancer (primary or metastatic).
* Have a history of an active hematologic malignancy within the past 2 years.
* Have an underlying diagnosis or disease state associated with an increased risk of bleeding (i.e., coagulopathies, HIV).
* Have a serious infection requiring intravenous antibiotic therapy during screening.
* Females who are pregnant, lactating, or have a positive serum pregnancy test during the screening period.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No